- Home
- BCDA vs LGVN Comparison
BCDA vs LGVN Comparison
Compare BCDA & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- LGVN
- Stock Information
- Founded
- BCDA N/A
- LGVN 2014
- Country
- BCDA United States
- LGVN United States
- Employees
- BCDA N/A
- LGVN N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- BCDA Health Care
- LGVN Health Care
- Exchange
- BCDA Nasdaq
- LGVN Nasdaq
- Market Cap
- BCDA 7.9M
- LGVN 25.9M
- IPO Year
- BCDA N/A
- LGVN 2021
- Fundamental
- Price
- BCDA $2.68
- LGVN $2.09
- Analyst Decision
- BCDA Strong Buy
- LGVN Strong Buy
- Analyst Count
- BCDA 1
- LGVN 2
- Target Price
- BCDA $25.00
- LGVN $8.00
- AVG Volume (30 Days)
- BCDA 73.1K
- LGVN 393.6K
- Earning Date
- BCDA 11-06-2024
- LGVN 11-08-2024
- Dividend Yield
- BCDA N/A
- LGVN N/A
- EPS Growth
- BCDA N/A
- LGVN N/A
- EPS
- BCDA N/A
- LGVN N/A
- Revenue
- BCDA $428,000.00
- LGVN $1,229,000.00
- Revenue This Year
- BCDA $6.92
- LGVN $161.78
- Revenue Next Year
- BCDA N/A
- LGVN $8.62
- P/E Ratio
- BCDA N/A
- LGVN N/A
- Revenue Growth
- BCDA 0.71
- LGVN 39.34
- 52 Week Low
- BCDA $1.96
- LGVN $0.77
- 52 Week High
- BCDA $23.25
- LGVN $23.90
- Technical
- Relative Strength Index (RSI)
- BCDA 49.01
- LGVN 54.70
- Support Level
- BCDA $2.39
- LGVN $1.76
- Resistance Level
- BCDA $2.90
- LGVN $2.26
- Average True Range (ATR)
- BCDA 0.18
- LGVN 0.12
- MACD
- BCDA -0.00
- LGVN 0.05
- Stochastic Oscillator
- BCDA 53.70
- LGVN 66.00
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.